Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 4 of Short Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

SECTION 4

Description of the concentration

The proposed transaction (the “Transaction”) consists in the acquisition, via a public tender offer, and within the meaning of Articles 3(1)(b) and 4 of the European Union Merger Regulation, of joint control over Eurobio Scientific SA (“Eurobio”) and its direct and indirect subsidiaries (“Eurobio”) by IK X Luxco 3 S.à.r.l (controlled by IK X Funds), ultimately managed and advised by IK Investment Partners S.à.r.l (“IK Partners”), on the one hand, and by NextStage AM (“NextStage”), through EBN, on the other hand (together, the “Notifying Parties” or the “Parties”). Eurobio is currently exclusively controlled by NextStage.

• IK Partners: is a European private equity firm headquartered in Luxembourg with offices across various Northern European countries focusing on making investments in the mid-market segment. Currently, it manages and advises funds, which pool capital from third-party investors and, since inception, it has invested in over 180 companies.

• NextStage: is an independent portfolio management company headquarted in France which supports innovative and growth-oriented French and European mid-sized companies in their development with its multi-strategy capital-investment platform.

• Eurobio Scientific: is a listed company headquarted in France, active in the diagnostics sector, from research to the marketing of specialty diagnostic products and products for life sciences research.

Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË - Tel. +32 22991111